

21<sup>st</sup> March, 2017

<b>BSE Limited</b> Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001 <b><u>Scrip Code: 532300</u></b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 <b><u>NSE Symbol – WOCKPHARMA</u></b>
---	--

Dear Sirs,

This is to inform the Exchanges that abbreviated new drug application ('ANDA') of Piperacillin and Tazobactam for Injection USP, 40.5 g/vial, pharmacy bulk package submitted by Wockhardt Bio AG (Wockhardt), Subsidiary of the Company has been approved by U.S. Food and Drug Administration ('USFDA'). Wockhardt's ANDA was determined to be therapeutically equivalent to the reference listed drug (RLD) Zosyn for Injection 40.5g/vial, pharmacy bulk package of Wyeth Pharmaceuticals Inc.

Wockhardt Bio AG had filed this ANDA in collaboration with Fresenius Kabi, Italy ('FKAI'), where the product development was completed. The ANDA will be manufactured commercially at FKAI, Mitim, Italy.

Kindly take the same on records please.

Thanking you,

for **Wockhardt Limited**



**Narendra Singh**  
**Company Secretary**

